Analysts Offer Predictions for Spark Therapeutics, Inc.’s Q1 2018 Earnings (ONCE)
Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at William Blair issued their Q1 2018 earnings per share estimates for Spark Therapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst R. Prasad forecasts that the biotechnology company will post earnings of ($1.99) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.73) EPS, Q3 2018 earnings at ($1.09) EPS, Q4 2018 earnings at ($1.22) EPS and FY2018 earnings at ($6.02) EPS.
ONCE has been the subject of several other reports. Jefferies Group LLC assumed coverage on Spark Therapeutics in a report on Monday, July 10th. They issued a “buy” rating and a $85.00 price objective for the company. Cantor Fitzgerald lifted their price objective on Spark Therapeutics to $105.00 and gave the company an “overweight” rating in a report on Friday. Cowen and Company reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a report on Friday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $90.58.
Shares of Spark Therapeutics (NASDAQ ONCE) traded down 0.97% on Thursday, hitting $85.36. The company had a trading volume of 1,204,764 shares. The company’s market capitalization is $2.67 billion. The firm has a 50-day moving average price of $85.92 and a 200 day moving average price of $85.92. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.04) earnings per share.
A number of hedge funds have recently modified their holdings of ONCE. Nationwide Fund Advisors grew its position in Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after acquiring an additional 414 shares during the last quarter. Bank of New York Mellon Corp grew its position in Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after acquiring an additional 10,916 shares during the last quarter. American International Group Inc. grew its position in Spark Therapeutics by 17.4% during the 1st quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after acquiring an additional 1,714 shares during the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in Spark Therapeutics during the 1st quarter worth $572,000. Finally, Principal Financial Group Inc. grew its position in Spark Therapeutics by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.
In related news, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total transaction of $127,500.00. Following the sale, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Katherine A. High sold 10,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $72.53, for a total value of $725,300.00. Following the sale, the insider now owns 220,000 shares in the company, valued at approximately $15,956,600. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last 90 days. 7.30% of the stock is currently owned by corporate insiders.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.